Literature DB >> 12107190

Transgenic overexpression of interleukin (IL)-10 in the lung causes mucus metaplasia, tissue inflammation, and airway remodeling via IL-13-dependent and -independent pathways.

Chun Geun Lee1, Robert J Homer, Lauren Cohn, Holger Link, Sungsoo Jung, Joseph E Craft, Barney S Graham, Teresa R Johnson, Jack A Elias.   

Abstract

To address the complex chronic effector properties of interleukin (IL)-10, we generated transgenic mice in which IL-10 was overexpressed in the lung. In these mice, IL-10 inhibited endotoxin-induced tumor necrosis factor production and neutrophil accumulation. IL-10 also caused mucus metaplasia, B and T cell-rich inflammation, and subepithelial fibrosis and augmented the levels of mRNA encoding Gob-5, mucins, and IL-13. In mice bred to have null mutations of IL-13, IL-4R(alpha), or STAT-6, transgenic IL-10 did not induce mucus metaplasia but did induce inflammation and fibrosis. IL-10 was also a critical mucin regulator of virus-induced mucus metaplasia. Thus, IL-10, although inhibiting lipopolysaccharide-induced inflammation, also causes mucus metaplasia, tissue inflammation, and airway fibrosis. These responses are mediated by multiple mechanisms with mucus metaplasia being dependent on and the inflammation and fibrosis being independent of an IL-13/IL-4R(alpha)/STAT-6 activation pathway.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12107190     DOI: 10.1074/jbc.M206395200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  49 in total

Review 1.  Fibrotic disease and the T(H)1/T(H)2 paradigm.

Authors:  Thomas A Wynn
Journal:  Nat Rev Immunol       Date:  2004-08       Impact factor: 53.106

Review 2.  Pathogenesis of respiratory syncytial virus infection in the murine model.

Authors:  R Stokes Peebles; Barney S Graham
Journal:  Proc Am Thorac Soc       Date:  2005

3.  Latent infection by γherpesvirus stimulates profibrotic mediator release from multiple cell types.

Authors:  Joshua S Stoolman; Kevin M Vannella; Stephanie M Coomes; Carol A Wilke; Thomas H Sisson; Galen B Toews; Bethany B Moore
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2010-10-29       Impact factor: 5.464

Review 4.  Mucin overproduction in chronic inflammatory lung disease.

Authors:  Hans-Peter Hauber; Susan C Foley; Qutayba Hamid
Journal:  Can Respir J       Date:  2006-09       Impact factor: 2.409

Review 5.  Transgenic modelling of cytokine polarization in the lung.

Authors:  Charles S Dela Cruz; Min-Jong Kang; Won-Kyung Cho; Chun Geun Lee
Journal:  Immunology       Date:  2010-11-23       Impact factor: 7.397

6.  Tissue inhibitor of metalloproteinase-1 modulates allergic lung inflammation in murine asthma.

Authors:  Mark F Sands; Patricia J Ohtake; Supriya D Mahajan; Shervin S Takyar; Ravikumar Aalinkeel; Yisheng V Fang; Jessica W Blume; Barbara A Mullan; Don E Sykes; Sandra Lachina; Paul R Knight; Stanley A Schwartz
Journal:  Clin Immunol       Date:  2008-10-26       Impact factor: 3.969

7.  Acellular pertussis vaccine protects against exacerbation of allergic asthma due to Bordetella pertussis in a murine model.

Authors:  Darren P Ennis; Joseph P Cassidy; Bernard P Mahon
Journal:  Clin Diagn Lab Immunol       Date:  2005-03

8.  Inhalation treatment of pulmonary fibrosis by liposomal prostaglandin E2.

Authors:  Vera Ivanova; Olga B Garbuzenko; Kenneth R Reuhl; David C Reimer; Vitaly P Pozharov; Tamara Minko
Journal:  Eur J Pharm Biopharm       Date:  2012-12-08       Impact factor: 5.571

Review 9.  Th9 and allergic disease.

Authors:  Pejman Soroosh; Taylor A Doherty
Journal:  Immunology       Date:  2009-08       Impact factor: 7.397

10.  Role of breast regression protein 39 (BRP-39)/chitinase 3-like-1 in Th2 and IL-13-induced tissue responses and apoptosis.

Authors:  Chun Geun Lee; Dominik Hartl; Gap Ryol Lee; Barbara Koller; Hiroshi Matsuura; Carla A Da Silva; Myung Hyun Sohn; Lauren Cohn; Robert J Homer; Alexander A Kozhich; Alison Humbles; Jennifer Kearley; Anthony Coyle; Geoffrey Chupp; Jennifer Reed; Richard A Flavell; Jack A Elias
Journal:  J Exp Med       Date:  2009-05-04       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.